Dr. Pardee Provides an Update on CPI-613

Timothy S. Pardee, MD
Published Online: Friday, December 20, 2013
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

CPI-613 attacks cancer cells in a different way, Pardee says, hitting the mitochondria and altering the ability of the cells to make the building blocks of the next cancer cell. In the trial, 40% of the 21 evaluable, heavily-pretreated patients responded. Researchers also observed several outstanding responses.

Researchers saw some evidence of acute renal failure as well as nausea and diarrhea associated with the trial, however, no myelosuppression was observed. There are a number of ongoing trials using this drug.

Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
More Reading
$auto_registration$